Printer Friendly

Daiichi Sankyo to license methylthioninium chloride solution for methaemoglobinaemia.

M2 PHARMA-November 25, 2011-Daiichi Sankyo to license methylthioninium chloride solution for methaemoglobinaemia(C)2011 M2 COMMUNICATIONS

25 November 2011 - Japanese pharmaceutical company Daiichi Sankyo Co Ltd (TYO:4568) said Friday it has signed a licence agreement for the development of Methylthioninium chloride solution for injection from French Provepharm SAS, for the treatment of life-threatening medicinal and chemical products induced methaemoglobinaemia in Japan.

Methylthioninium chloride has not been approved in Japan, but only cleared by the European Medicines Agency (EMA) and used to treat methaemoglobinaemia in Europe, known as Methylthioninium chloride Proveblue 5mg/ml, solution for injection.

People who suffer from methaemoglobinaemia have high blood methaemoglobin concentration with usual symptoms like cyanosis, headache, dizziness, shortness of breath, and loss of consciousness.

((Comments on this story may be sent to

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Nov 25, 2011
Previous Article:Epax says AKR963 meets efficacy endpoints in Phase 3 study.
Next Article:Affitech's Q3 2011 net loss narrows.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters